Related Experiment Video

Updated: Jul 16, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

[Drug trials in humans. Risks in the light of the London catastrophe]

A Otte1

  • 1Zentrum Klinische Studien, Universitätsklinikum Freiburg, Elsässer Strasse 2, 79110 Freiburg, Germany. andreas.otte@uniklinik-freiburg.de

Der Internist
|February 20, 2007
PubMed

Insights

The TGN1412 drug trial caused severe adverse events due to a cytokine storm. This highlights the inherent risks in drug development, even in later phases, emphasizing the need for stringent regulatory oversight.

Area of Science:

  • Drug development
  • Clinical trials
  • Immunology

Background:

  • The first-in-man trial of TGN1412, an anti-CD28 monoclonal antibody, led to severe adverse events.
  • These events were caused by an unexpected cytokine storm, a critical risk in drug testing.

Purpose of the Study:

  • To analyze potential mistakes and consequences in the TGN1412 trial.
  • To discuss broader risks in drug development and clinical testing.
  • To examine the evolution of regulatory requirements for drug trials.

Main Methods:

  • Review of the TGN1412 trial incident.
  • Analysis of drug development risks across different clinical phases.
  • Examination of historical drug safety cases (e.g., Vioxx).

Main Results:

  • The TGN1412 trial demonstrated severe risks associated with first-in-man studies.
  • Drug development risks can manifest in later phases or post-market.
  • Regulatory requirements have improved but require continuous adaptation.

Conclusions:

  • Drug development, especially with novel immunotherapies like TGN1412, carries significant risks.
  • Vigilance and robust regulatory frameworks are essential throughout the drug lifecycle.
  • Lessons learned from incidents like TGN1412 drive improvements in patient safety and trial design.

More Related Videos

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...